Recombinant human thrombomodulin in acute exacerbation of idiopathic pulmonary fibrosis

Chest

Volumn 148, Issue 2, 2015, Pages 436-443

  Kataoka, Kensuke ^a   Taniguchi, Hiroyuki ^a   Kondoh, Yasuhiro ^a   Nishiyama, Osamu ^b   Kimura, Tomoki ^a   Matsuda, Toshiaki ^a   Yokoyama, Toshiki ^a   Sakamoto, Koji ^c   Ando, Masahiko ^d  

^a TOSEI GENERAL HOSPITAL   (Japan)

^b KINKI UNIVERSITY   (Japan)

^c NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^d NAGOYA UNIVERSITY HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CYCLOSPORIN; D DIMER; LOW MOLECULAR WEIGHT HEPARIN; METHYLPREDNISOLONE; PIRFENIDONE; RECOMBINANT THROMBOMODULIN; THROMBOMODULIN; RECOMBINANT PROTEIN; THBD PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; CASE CONTROL STUDY; CLINICAL ARTICLE; CONTINUOUS INFUSION; CONTROLLED STUDY; CONVALESCENCE; DEEP VEIN THROMBOSIS; DISEASE EXACERBATION; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ENDOTRACHEAL INTUBATION; FEMALE; FIBROSING ALVEOLITIS; HEMOPTYSIS; HUMAN; INJECTION SITE BLEEDING; LOGISTIC REGRESSION ANALYSIS; MALE; MORTALITY; NONINVASIVE VENTILATION; PREDICTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SUBCUTANEOUS HEMORRHAGE; SURVIVAL RATE; TREATMENT DURATION; TREATMENT OUTCOME; UNIVARIATE ANALYSIS; VERY ELDERLY; DISEASE COURSE; EPIDEMIOLOGY; IDIOPATHIC PULMONARY FIBROSIS; METABOLISM; MIDDLE AGED; PROGNOSIS; STATISTICAL MODEL;

AGED; C-REACTIVE PROTEIN; DISEASE PROGRESSION; FEMALE; HISTORICALLY CONTROLLED STUDY; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; LOGISTIC MODELS; MALE; MIDDLE AGED; PROGNOSIS; RECOMBINANT PROTEINS; THROMBOMODULIN; TREATMENT OUTCOME;

EID: 84939236841     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.14-2746     Document Type: Article

References (28)

1. Ley B, Collard HR, King TE Jr. Clinical course and prediction of survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2011; 183 (4): 431-440.
2. Kubo H, Nakayama K, Yanai M, et al. Anticoagulant therapy for idiopathic pulmonary fibrosis. C hest. 2005; 128 (3): 1475-1482.
3. Collard HR, Calfee CS, Wolters PJ, et al. Plasma biomarker profiles in acute exacerbation of idiopathic pulmonary fibrosis . Am J Physiol Lung Cell Mol Physiol. 2010; 299 (1): L3-L7.
4. Günther A, Mosavi P, Ruppert C, et al. Enhanced tissue factor pathway activity and fibrin turnover in the alveolar compartment of patients with interstitial lung disease. Thromb Haemost. 2000; 83 (6): 853-860.
5. Olman MA. Mechanisms of fibroproliferation in acute lung injury. In: Matthay MA, Lenfant C, eds. A cute Respiratory Distress Syndrome. New York, NY: Marcel Dekker; 2003: 313-354.
6. Martinez FJ, Safrin S, Weycker D, et al; IPF Study Group. The clinical course of patients with idiopathic pulmonary fibrosis . Ann Intern Med. 2005; 142 (12 pt 1): 963-967.
7. Gaggar A, Olman MA. Biologic markers of mortality in acute lung injury. Clin Chim Acta. 2006; 372 (1-2): 24-32.
8. Prabhakaran P, Ware LB, White KE, Cross MT, Matthay MA, Olman MA. Elevated levels of plasminogen activator inhibitor-1 in pulmonary edema fluid are associated with mortality in acute lung injury. Am J Physiol Lung Cell Mol Physiol. 2003; 285 (1): L20-L28.
9. Ware LB, Fang X, Matthay MA. Protein C and thrombomodulin in human acute lung injury. Am J Physiol Lung Cell Mol Physiol. 2003; 285 (3): L514-L521.
10. Collard HR, Moore BB, Flaherty KR, et al; Idiopathic Pulmonary Fibrosis Clinical Research Network Investigators. Acute exacerbations of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2007; 176 (7): 636-643.
11. Raghu G, Collard HR, Egan JJ, et al; ATS/ERS/JRS/ALAT Committee on Idiopathic Pulmonary Fibrosis. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and manage ment. Am J Respir Crit Care Med. 2011; 183(6): 788-824.
12. Kondoh Y, Taniguchi H, Kawabata Y, Yokoi T, Suzuki K, Takagi K. Acute exacerbation in idiopathic pulmonary fibrosis. Analysis of clinical and pathologic findings in three cases. Chest. 1993; 103 (6): 1808-1812.
13. Maruyama I. Recombinant thrombomodulin and activated protein C in the treatment of disseminated intravascular coagulation. Thromb Haemost. 1999; 82 (2): 718-721.
14. Conway EM. Thrombomodulin and its role in inflammation. S emin Immunopathol. 2012; 34 (1): 107-125.
15. Saito H, Maruyama I, Shimazaki S, et al. Efficacy and safety of recombinant human soluble thrombomodulin (ART-123) in disseminated intravascular coagulation: results of a phase III, randomized, double-blind clinical trial. J Thromb Haemost. 2007; 5 (1): 31-41.
16. Ogawa Y, Yamakawa K, Ogura H, et al. Recombinant human soluble thrombomodulin improves mortality and respiratory dysfunction in patients with severe sepsis. J Trauma Acute Care Surg. 2012; 72 (5): 1150-1157.
17. Yamakawa K, Fujimi S, Mohri T, et al. Treatment effects of recombinant human soluble thrombomodulin in patients with severe sepsis: a historical control study. Crit Care. 2011; 15 (3): R123.
18. Ebina M, Taniguchi H, Miyasho T, et al. Gradual increase of high mobility group protein b1 in the lungs aft er the onset of acute exacerbation of idiopathic pulmonary fibrosis. P ulm Med. 2011; 2011: 916486.
19. Noth I, Anstrom KJ, Calvert SB, et al; Idiopathic Pulmonary Fibrosis Clinical Research Network (IPFnet). A placebocontrolled randomized trial of warfarin in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2012; 186 (1): 88-95.
20. Song JW, Hong SB, Lim CM, Koh Y, Kim DS. Acute exacerbation of idiopathic pulmonary fibrosis: incidence, risk factors and outcome. Eur Respir J. 2011; 37 (2): 356-363.
21. Shi CS, Shi GY, Hsiao HM, et al. Lectinlike domain of thrombomodulin binds to its specific ligand Lewis Y antigen and neutralizes lipopolysaccharideinduced inflammatory response. Blood. 2008; 112 (9): 3661-3670.
22. Abeyama K, Stern DM, Ito Y, et al. The N-terminal domain of thrombomodulin sequesters high-mobility group-B1 protein, a novel antiinflammatory mechanism. J Clin Invest. 2005; 115 (5): 1267-1274.
23. Van de Wouwer M, Plaisance S, De Vriese A, et al. The lectin-like domain of thrombomodulin interferes with complement activation and protects against arthritis. J Thromb Haemost. 2006; 4 (8): 1813-1824.
24. Ito T, Maruyama I. Thrombomodulin: protectorate God of the vasculature in thrombosis and inflammation. J Thromb Haemost. 2011; 9 (suppl 1): 168-173.
25. Sakamoto S, Homma S, Miyamoto A, Kurosaki A, Fujii T, Yoshimura K. Cyclosporin A in the treatment of acute exacerbation of idiopathic pulmonary fibrosis. I ntern Med. 2010; 49 (2): 109-115.
26. Homma S, Sakamoto S, Kawabata M, et al. Cyclosporin treatment in steroidresistant and acutely exacerbated interstitial pneumonia. Intern Med. 2005; 44 (11): 1144-1150.
27. Inase N, Sawada M, Ohtani Y, et al. Cyclosporin A followed by the treatment of acute exacerbation of idiopathic pulmonary fibrosis with corticosteroid. Intern Med. 2003; 42 (7): 565-570.
28. Yokoyama T, Kondoh Y, Taniguchi H, et al. Noninvasive ventilation in acute exacerbation of idiopathic pulmonary fibrosis. Intern Med. 2010; 49 (15): 1509-1514.